EP0708658A4 - Rekombinanter cytomegalovirusimpfstoff - Google Patents

Rekombinanter cytomegalovirusimpfstoff

Info

Publication number
EP0708658A4
EP0708658A4 EP94915386A EP94915386A EP0708658A4 EP 0708658 A4 EP0708658 A4 EP 0708658A4 EP 94915386 A EP94915386 A EP 94915386A EP 94915386 A EP94915386 A EP 94915386A EP 0708658 A4 EP0708658 A4 EP 0708658A4
Authority
EP
European Patent Office
Prior art keywords
vaccine containing
recombinant cytomegalovirus
cytomegalovirus
recombinant
vaccine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP94915386A
Other languages
English (en)
French (fr)
Other versions
EP0708658A1 (de
Inventor
Stanley A Plotkin
Robert P Ricciardi
Eva Gonczol
Klara Berencsi
Robert F Rando
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wistar Institute of Anatomy and Biology
US Department of Health and Human Services
Original Assignee
Wistar Institute of Anatomy and Biology
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wistar Institute of Anatomy and Biology, US Department of Health and Human Services filed Critical Wistar Institute of Anatomy and Biology
Publication of EP0708658A1 publication Critical patent/EP0708658A1/de
Publication of EP0708658A4 publication Critical patent/EP0708658A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
EP94915386A 1993-04-16 1994-04-15 Rekombinanter cytomegalovirusimpfstoff Withdrawn EP0708658A4 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4897893A 1993-04-16 1993-04-16
US48978 1993-04-16
PCT/US1994/004180 WO1994023744A1 (en) 1993-04-16 1994-04-15 Recombinant cytomegalovirus vaccine

Publications (2)

Publication Number Publication Date
EP0708658A1 EP0708658A1 (de) 1996-05-01
EP0708658A4 true EP0708658A4 (de) 1997-05-21

Family

ID=21957451

Family Applications (1)

Application Number Title Priority Date Filing Date
EP94915386A Withdrawn EP0708658A4 (de) 1993-04-16 1994-04-15 Rekombinanter cytomegalovirusimpfstoff

Country Status (3)

Country Link
EP (1) EP0708658A4 (de)
CA (1) CA2160583A1 (de)
WO (1) WO1994023744A1 (de)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5591439A (en) * 1989-03-24 1997-01-07 The Wistar Institute Of Anatomy And Biology Recombinant cytomegalovirus vaccine
US5997878A (en) * 1991-03-07 1999-12-07 Connaught Laboratories Recombinant poxvirus-cytomegalovirus, compositions and uses
WO1997040165A1 (en) 1996-04-23 1997-10-30 The Wistar Institute Of Anatomy And Biology Novel human cytomegalovirus dna constructs and uses therefor
WO1998034635A1 (en) * 1997-02-07 1998-08-13 The Wistar Institute Methods and compositions for the inhibition of interleukin-12 production
AU4323599A (en) 1998-05-29 1999-12-13 Instituto Superiore Di Sanita Compositions and methods for use in affecting hematopoietic stem cell populations in mammals
US6420545B1 (en) 1999-05-24 2002-07-16 The Trustees Of The University Of Pennsylvania CD4-independent HIV envelope proteins as vaccines and therapeutics
US6846486B1 (en) 2000-02-24 2005-01-25 Advanced Biotherapy Concepts, Inc. Method of treating allergy by administering an anti-histamine antibody
US7223563B2 (en) 2000-07-19 2007-05-29 Advanced Research And Technology Institute Fibroblast growth factor (FGF23) nucleic acids
EP1404713A4 (de) 2001-05-24 2004-09-22 Human Dna Technology Inc Neues keratinocyte growth factor 2 analogon in haarfollikeln
AUPR593101A0 (en) * 2001-06-26 2001-07-19 Council Of The Queensland Institute Of Medical Research, The Cytomegalovirus t cell epitopes
US7176278B2 (en) 2001-08-30 2007-02-13 Biorexis Technology, Inc. Modified transferrin fusion proteins
US20060130158A1 (en) 2002-08-30 2006-06-15 Turner Andrew J Modified transferrin fusion proteins comprising duplicate transferrin amino or carboxy terminal domains
EP1613269B1 (de) 2003-04-04 2015-02-25 Incyte Corporation Zusammensetzungen, verfahren und kits in zusammenhang mit her-2 spaltung
CA2568344C (en) 2004-05-27 2016-01-19 The Trustees Of The University Of Pennsylvania Novel artificial antigen presenting cells and uses therefor
US7608433B2 (en) 2005-02-09 2009-10-27 Idexx Laboratories Method of detection of classical swine fever
MX336958B (es) 2005-11-15 2016-02-05 Philadelphia Children Hospital Metodos y composiciones para modular la hemostasia.
AU2005339101B2 (en) 2005-12-14 2013-01-10 Herantis Pharma Plc. Novel neurotrophic factor protein and uses thereof
CA2641519A1 (en) 2006-02-23 2007-09-07 The Children's Hospital Of Philadelphia Compositions and methods for modulating hemostasis using variant forms of activated factor v
ES2535358T3 (es) 2006-12-12 2015-05-08 Biorexis Pharmaceutical Corporation Bibliotecas de proteínas de fusión de transferrina
FI20070808A0 (fi) 2007-10-25 2007-10-25 Mart Saarma GDNF:n silmukointivariantit ja niiden käytöt
FI20080326A0 (fi) 2008-04-30 2008-04-30 Licentia Oy Neurotroofinen tekijä MANF ja sen käytöt
US8557762B2 (en) 2008-11-21 2013-10-15 The Children's Hospital Of Philadelphia Snake factor V and methods of use thereof as a procoagulant
WO2012074868A2 (en) 2010-12-03 2012-06-07 Ms Technologies, Llc Optimized expression of glyphosate resistance encoding nucleic acid molecules in plant cells
US9371522B2 (en) 2011-09-30 2016-06-21 The Children's Hospital Of Philadelphia Compositions and methods for modulating hemostasis
US9783817B2 (en) 2013-03-04 2017-10-10 Arkansas State University Methods of expressing and detecting activity of expansin in plant cells
WO2014191630A2 (en) 2013-05-28 2014-12-04 Helsingin Yliopisto Non-human animal model encoding a non-functional manf gene
PE20231949A1 (es) 2015-10-30 2023-12-05 Spark Therapeutics Inc VARIANTES DEL FACTOR VIII REDUCIDO CON CpG, COMPOSICIONES Y METODOS Y USOS PARA EL TRATAMIENTO DE TRASTORNOS DE LA HEMOSTASIA
KR20250030036A (ko) 2017-06-07 2025-03-05 스파크 테라퓨틱스, 인코포레이티드 개선된 세포 트랜스펙션 및/또는 rAAV 벡터 생산을 위한 증진제
WO2019152957A1 (en) 2018-02-02 2019-08-08 Arizona Board Of Regents On Behalf Of Arizona State University Dna-chimeric antigen receptor t cells for immunotherapy
EP4229204A1 (de) 2020-10-15 2023-08-23 F. Hoffmann-La Roche AG Nukleinsäurekonstrukte zur gleichzeitigen genaktivierung
KR20230085929A (ko) 2020-10-15 2023-06-14 에프. 호프만-라 로슈 아게 Va rna 전사를 위한 핵산 구조체
WO2023198685A1 (en) 2022-04-13 2023-10-19 F. Hoffmann-La Roche Ag Method for determining aav genomes
CN119256220A (zh) 2022-05-23 2025-01-03 豪夫迈·罗氏有限公司 用于区分aav颗粒血清型和aav颗粒荷载状态的基于拉曼的方法
EP4532737A1 (de) 2022-06-03 2025-04-09 F. Hoffmann-La Roche AG Verfahren zur herstellung rekombinanter aav-partikel
KR20250036743A (ko) 2022-07-14 2025-03-14 에프. 호프만-라 로슈 아게 재조합 aav 입자를 생산하는 방법
EP4744752A1 (de) 2022-09-12 2026-05-20 Hoffmann La Roche Verfahren zur trennung von vollen und leeren aav-partikeln
IL322001A (en) 2023-02-07 2025-09-01 Hoffmann La Roche Method for detecting antibodies to anti-AAV particles
EP4683676A1 (de) 2023-03-21 2026-01-28 F. Hoffmann-La Roche AG Verfahren zur herstellung von rekombinanten aav-partikelpräparaten
WO2025168663A1 (en) 2024-02-09 2025-08-14 F. Hoffmann-La Roche Ag Method for producing recombinant adeno-associated viral particles
WO2025252480A1 (en) 2024-06-07 2025-12-11 F. Hoffmann-La Roche Ag Method for purifying plasmid dna
WO2026022064A1 (en) 2024-07-22 2026-01-29 F. Hoffmann-La Roche Ag Novel aav rep orfs and rep polypeptides
WO2026037757A1 (en) 2024-08-13 2026-02-19 F. Hoffmann-La Roche Ag Modified aav particles

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990000062A1 (en) * 1988-07-01 1990-01-11 The Children's Hospital, Incorporated Antibody recognition of fragments from cytomegalovirus
WO1990006771A1 (en) * 1988-12-12 1990-06-28 The Children's Hospital, Incorporated Proteolytic fragments obtained from human cytomegalovirus glycoprotein complex i
EP0389286A2 (de) * 1989-03-24 1990-09-26 The Wistar Institute Of Anatomy And Biology Rekombinanter Cytomegalovirus-Impfstoff
WO1990011302A1 (en) * 1989-03-24 1990-10-04 University Of Iowa Research Foundation Antibody and t cell recognition sites on glycoproteins

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA858044B (en) * 1984-11-01 1987-05-27 American Home Prod Oral vaccines

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990000062A1 (en) * 1988-07-01 1990-01-11 The Children's Hospital, Incorporated Antibody recognition of fragments from cytomegalovirus
WO1990006771A1 (en) * 1988-12-12 1990-06-28 The Children's Hospital, Incorporated Proteolytic fragments obtained from human cytomegalovirus glycoprotein complex i
EP0389286A2 (de) * 1989-03-24 1990-09-26 The Wistar Institute Of Anatomy And Biology Rekombinanter Cytomegalovirus-Impfstoff
WO1990011302A1 (en) * 1989-03-24 1990-10-04 University Of Iowa Research Foundation Antibody and t cell recognition sites on glycoproteins

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BERENCSI ET AL: "HUMAN CYTOMEGALOVIRUS (HCMV) GLYCOPROTEIN-B (GB)-SPECIFIC CELL-MEDIATED IMMUNITY IN EXPERIMENTAL ANIMALS", ACTA MICROBIOLOGICA HUNGARICA, vol. 38, 1991, pages 170 - 171, XP000645013 *
BERENCSI ET AL: "MURINE CYTOTOXIC T CELL RESPONSE SPECIFIC FOR HUMAN CYTOMEGALOVIRUS GLYCOPROTEIN B (GB) INDUCED BY ADENOVIRUS AND VACCINIA VIRUS RECOMBINANTS EXPRESSING GB", JOURNAL OF GENERAL VIROLOGY, vol. 74, November 1993 (1993-11-01), pages 2507 - 2512, XP002026070 *
LIU ET AL: "THE N-TERIMINAL 513 AMINO ACIDS OF THE ENVELOPE GLYCOPROTEIN GB OF HUMAN CYTOMEGALOVIRUS STIMLATES BOTH B- AND T-CELL IMMUNE RESPONSES IN HUMANS", JOURNAL OF VIROLOGY, vol. 65, no. 3, March 1991 (1991-03-01), pages 1644 - 1648, XP000645036 *
See also references of WO9423744A1 *

Also Published As

Publication number Publication date
WO1994023744A1 (en) 1994-10-27
CA2160583A1 (en) 1994-10-27
EP0708658A1 (de) 1996-05-01

Similar Documents

Publication Publication Date Title
DK0761231T3 (da) Vaccinepræparat indeholdende adjuvanser
FI955667L (fi) Adjuvantteja RS-viruksen vastaisia rokotteita varten
ATE151627T1 (de) Saugflasche
FI945811A7 (fi) Des-Tyr-dynorfiinianalogeja
FI944052A0 (fi) Oraalinen rokote
PL307402A1 (en) Vaccine containing a hepatitis a virus
IL104419A0 (en) Insecticidally effective peptides
FI953001L (fi) Insuliinianalogeja
DE69328718D1 (de) Verbesserte blisterpackungen
IL101639A0 (en) Recombinant influenza vaccines
FI943418L (fi) Synteettiset peptidit vihurirokkorokotetta varten
FI944428A7 (fi) Viruksen vastaisia peptidejä
FI924395A7 (fi) Ei-A eikä B-peptidejä
GB9321345D0 (en) Instant nail mask
DK136492D0 (da) A pharmaceutical formulation
ITMI922675A1 (it) Peptidi immunogenici
NO943251D0 (no) Oral vaksine
GB9323820D0 (en) Vaccine
GB9213116D0 (en) Artificial finger nails
ITMI922963A1 (it) Peptidi ciclici
SE9203057D0 (sv) New vaccine against schistosomiasis
GB9206789D0 (en) Vaccine
GB9206788D0 (en) Vaccine
GB9222156D0 (en) Vaccine
GB9206797D0 (en) Vaccine

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19951106

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

RHK1 Main classification (correction)

Ipc: C12N 15/00

A4 Supplementary search report drawn up and despatched

Effective date: 19970404

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 19990316

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20030730